SCA
OMED

SAC Capital Advisors’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

SAC Capital Advisors’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-38,893
Closed -$595K – 2190
2013
Q3 		$595K Buy
+38,893
New +$721K ﹤0.01% 1082

Other funds holding OMED

SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAC Capital Advisors's OMED Position: Q4 2013 in Review

SAC Capital Advisors sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2013, closing a stake of 38,893 shares — an estimated $595K sold.

SAC Capital Advisors first reported a position in OMED in Q3 2013 and held it in 1 quarter. The position peaked at $595K in Q3 2013. 55 funds tracked by Wall St. Rank hold OMED as of Q4 2013.

  • SAC Capital Advisors reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2013 after selling out during the quarter.
  • SAC Capital Advisors sold 38,893 OncoMed Pharmaceuticals, Inc. shares in Q4 2013, an estimated $595K.
  • SAC Capital Advisors first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 1 quarter.
  • SAC Capital Advisors's OncoMed Pharmaceuticals, Inc. position peaked at $595K in Q3 2013.
  • 55 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2013.

Based on SAC Capital Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.